Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.
Eva R
ER
Haspinger
Marina Chiara
MC
Garassino
Valter
V
Torri
Michela
M
Cinquini
Filippo
F
De Braud
Francesco
F
Gelsomino
D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000077716:Afatinib; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D011799:Quinazolines / Q000627:therapeutic use*
D011799:Quinazolines; D000077716:Afatinib; D066246:ErbB Receptors